Mighty Therapeutics Holdings Inc - Company Profile
Powered by 
All the sales intelligence you need on Mighty Therapeutics Holdings Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Mighty Therapeutics Holdings Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Mighty Therapeutics Holdings Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Mighty Therapeutics Holdings Inc (Mighty Therapeutics) is an innovative early-stage biopharmaceutical company. Its primary activity is to discover, develop, and commercialize novel therapies for mitochondrial dysfunction associated with genetic mitochondrial diseases and common age-related diseases. Mighty Therapeutics' interest areas are rare genetic disorders involving mitochondrial dysfunction; neurodegenerative disorders, and ophthalmic disorders. The company is currently investigating elamipretide for ophthalmic diseases entailing mitochondrial dysfunction, such as dry AMD, rare neuromuscular disorders, primary mitochondrial myopathy, Duchenne muscular dystrophy, and rare cardiomyopathies. It is also investigating SBT-272 for rare neurological disease indications, such as amyotrophic lateral sclerosis. The company collaborates with academic and medical institutions to advance its pipeline of targeted therapies. Mighty Therapeutics is headquartered in Needham, Massachusetts, the US.
Headquarters
United States of America
Address
Suite 201, 123 Highland Avenue, Needham, Massachusetts, 02494
Website
www.stealthbt.com
Telephone
1 617 6006888
Industry
Pharmaceuticals and Healthcare
Mighty Therapeutics Holdings Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Commercial Product: | Forzinity |
| Forzinitytm Injection - Mitochondrial Cardiolipin Binder | Mito Assist |
| Pipeline | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In May, the company entered into a licensing agreement with Pharmanovia to commercialize Elamipretide for the treatment of barth syndrome in europe and key global territories. |
| 2022 | Regulatory Approval | In November, the company's pipeline product SBT-272 Granted Orphan Drug Designation for Treatment of ALS. |
| 2022 | Contracts/Agreements | In August, the company agreed to merge with Morningside. |
Competitor Comparison
| Key Parameters | Mighty Therapeutics Holdings Inc | Regeneron Pharmaceuticals Inc | Apellis Pharmaceuticals Inc | Ionis Pharmaceuticals Inc | Alimera Sciences Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Needham | Tarrytown | Waltham | Carlsbad | Alpharetta |
| State/Province | Massachusetts | New York | Massachusetts | California | Georgia |
| No. of Employees | - | 15,410 | 733 | 1,402 | 159 |
| Entity Type | Private | Public | Private | Public | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Reenie McCarthy | Director; Chief Executive Officer | Executive Board | 2015 | - |
| David A. Brown, PhD | Chief Scientific Officer | Senior Management | 2026 | - |
| Brian Blakey | Chief Business Officer | Senior Management | 2014 | - |
| Jim Carr | Chief Clinical Development Officer | Senior Management | 2017 | - |
| Henry Hess | Chief Legal Counsel | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer